by Carole Tanzer Miller A drug used to help patients lose weight and manage diabetes may also help those with heart failure, an international clinical trial shows. The test of tirzepatide, brand named Zepbound, included 731 patients with diastolic heart failure and obesity who were followed for two years. “This class of drug continues to...
Tag: <span>Tirzepatide</span>
Post
How Are Doctors Using Tirzepatide vs Semaglutide? A Q&A
When prescribing glucagon-like peptide 1 (GLP-1) medications, many physicians prefer tirzepatide over the more well-known semaglutide due to its superior efficacy in weight loss and A1c reduction. Studies indicated that tirzepatide can lead to greater weight loss than semaglutide. Factors like insurance coverage, drug availability, and side effects also influence physicians’ choices, with some patients...
Post
Tirzepatide Leads to Long-Term Glucose Control
Medscape Medical News > Conference News > EASD 2024 Nancy A. Melville September 25, 2024 MADRID — The majority of patients achieving high rates of glucose control and weight loss in the first year of tirzepatide treatment have sustained success in the second year; however, factors predicting a sustained response are less clear for weight...
Post
Tirzepatide associated with greater weight loss in women than men
September 11, 2024 by Diabetologia Credit: Unsplash/CC0 Public DomainAll doses of tirzepatide, a medication approved in the EU to treat type 2 diabetes and obesity, consistently reduced body weight in women and men, but women experienced greater weight loss, according to new post hoc research to be presented at this year’s Annual Meeting of the...
Post
Large-scale population analysis confirms reassuring safety profile of tirzepatide
September 11, 2024by Diabetologia Credit: Unsplash/CC0 Public DomainAs more people with type 2 diabetes (T2D) are taking medications to help manage blood sugar levels and weight loss, concerns about whether these drugs are safe have emerged. Now real-world evidence from the FDA Adverse Event Reporting System (FAERS) database reveals a reassuring safety profile for tirzepatide...
Post
Beyond Diabetes: Tirzepatide Could Soon Be Approved for Obstructive Sleep Apnea (OSA) Treatment
Written by Sophie Vergnaud, MD | Reviewed by Alyssa Billingsley, PharmDPublished on May 3, 2024 Key takeaways: Tirzepatide (Zepbound) isn’t currently approved for the treatment of obstructive sleep apnea (OSA), but it could be as early as the end of 2024.People who could potentially benefit from the medication for OSA may already be eligible for...
Post
Tirzepatide for type 2 diabetes associated with lower risks for mortality, adverse heart, kidney events
August 12, 2024 by Elana Gotkine Risks for mortality, adverse heart, kidney events lower with tirzepatide for T2DMFor patients with type 2 diabetes, treatment with tirzepatide (a dual glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist) is associated with lower risks for all-cause mortality and adverse cardiovascular and kidney events compared with glucagon-like peptide...
Post
Tirzepatide Significantly Reduces Sleep Disruptions
Medscape Medical News > Conference News > ADA 2024 Alicia Ault June 22, 2024s ORLANDO, Fla. — The diabetes and weight loss drug tirzepatide (Mounjaro for type 2 diabetes; Zepbound for obesity) was so effective at reducing sleep disruptions in patients with obesity and obstructive sleep apnea (OSA) that 40% to 50% no longer needed...
Post
Tirzepatide found to reduce body weight, waist circumference in those with obesity regardless of duration of condition
by European Association for the Study of Obesity Credit: CC0 Public DomainNew research to be presented at this year’s European Congress on Obesity (Venice, Italy, May 12-15) shows that the obesity medication tirzepatide consistently reduces body weight and waist circumference regardless of the length of time the person has been living with overweight or obesity....
Post
Higher Weight Loss on Tirzepatide Links to Seven Factors
Mitchel L. Zoler, PhD October 26, 2023 TOPLINE: Among the 3188 people with type 2 diabetes who were adherent to their tirzepatide (Mounjaro, Lilly) regimen in four pivotal trials of the agent, a quarter achieved at least a 15% cut from their baseline body weight after 40–42 weeks of treatment, and researchers found seven baseline variables that...
- 1
- 2